SecMark Consultancy Limited (SECMARK)

-

SecMark Consultancy Ltd. operates as a consultancy firm. It provides Regulatory Compliance, Operations, Risk Management, Business Processes and Lives made simple with its Consulting, Technology and Outsourcing services. The company was founded on August 03, 2011 and is headquartered in Mumbai, MA.

SECMARK CONSULTANCY LIMITED financial statements, including revenue, expenses, and profit: The total revenue of SECMARK for the last quarter is 124.98 M INR, and it's 56.26% higher compared to the previous quarter. The net income of Q4 24 is 39.35 M INR.

SECMARK CONSULTANCY LIMITED revenue breakdown overview: The greatest contribution to the revenue figure was made by India — last year it brought SECMARK CONSULTANCY LIMITED 245.92 M INR, and the year before that — 174.37 M INR.

Potential 55%-60% Upside with Clear Entry Price 141, Target Price 218






Comments

Post a Comment

Popular posts from this blog

Max Healthcare Institute Limited (MAXHEALTH)

-
Image
Max Healthcare Institute Ltd. engages in the management and operation of hospitals and specialty clinics. Its services include domestic and international patient services, hospital network, preventive health plans, and medical and life saver training programs. The company was founded on January 1, 1985 is headquartered in Gurugram, India. Max Healthcare Institute Ltd financial statements, including revenue, expenses, and profit: The total revenue of MAXHEALTH for the last quarter is 20.28 B INR, and it's 6.17% higher compared to the previous quarter. The net income of Q1 25 is 3.08 B INR. Max Healthcare Institute Ltd key financial stats and ratios: MAXHEALTH price-to-sales ratio is 15.40. The company has an Enterprise Value to EBITDA ratio of 57.94. As of 2024 they employed 26.83 k people. Max Healthcare Institute Ltd dividends overview: MAXHEALTH dividends are paid annually. The last dividend per share was 1.50 INR. As of today, Dividend Yield (TTM)% is 0.13%. Max Healthcare In...
Read more

Pfizer Limited (PFIZER)

-
Image
Pfizer Ltd. engages in the business of manufacturing, marketing, trading, import and export of pharmaceutical products. Its product offerings include treatment for depression, erectile dysfunction, high cholesterol, human immunodeficiency virus infection, hypertension, bacterial infections and systemic fungal infections, and other chronic therapeutic which includes pain, respiratory, vitamins or minerals, hospital anti-infectives, neurosciences, and cardiovascular. The firm's products include Prevenar 13, Ativan, Zosyn, Minipress XL, Meronem, Enbrel, Dolonex, Magnex, Trulimax, Neksium, Becosules, Gelusil, Mucaine, Folvite, Autrin, Citralka, and Corex Range. It operates through the India and Outside of India geographical segments. The company was founded on November 21, 1950 and is headquartered in Mumbai, India. PFIZER LTD financial statements, including revenue, expenses, and profit: The total revenue of PFIZER for the last quarter is 5.92 B INR, and it's 10.02% higher compar...
Read more

Lloyds Metals & Energy Limited (LLOYDSME)

-
Image
Lloyds Metals & Energy Ltd. engages in the manufacturing, generation, and distribution of iron, steel, and power. It operates through the following segments: Sponge Iron, Power, and Mining. The Sponge Iron segment includes production and manufacturing of sponge iron. The Power segment refers to the extraction of iron ore from mines. The Mining segment focuses on the generation of power. The company was founded by Babulal Kesardeo Agarwal and Rajesh Rajnarayan Gupta on April 5, 1977 and is headquartered in Mumbai, India. LLOYDS METALS N ENERGY L financial statements, including revenue, expenses, and profit: The total revenue of LLOYDSME for the last quarter is 11.93 B INR, and it's 28.77% lower compared to the previous quarter. The net income of Q4 24 is 2.02 B INR. LLOYDS METALS N ENERGY L key financial stats and ratios: LLOYDSME price-to-sales ratio is 11.90. The company has an Enterprise Value to EBITDA ratio of 39.56. As of 2024 they employed 2.37 k people. LLOYDS METALS N...
Read more